Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: The TASTY-steering Study [NA]
A clinical trial update indicates that the TASTY-steering Study is currently recruiting for patients with metastatic triple-negative breast …
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer) [Phase 2]
This clinical trial update describes a Phase 2 study evaluating trilaciclib in combination with eribulin for locally advanced or metastatic …
-
CLINICAL_TRIALS research · 2025-11-28Clinical Trial Update: TRIple Negative Breast Cancer Markers In Liquid Biopsies Using Artificial Intelligence
A clinical trial evaluating biomarkers for triple-negative breast cancer in liquid biopsies using artificial intelligence, currently recruit…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer
The Netherlands Cancer Institute is conducting a trial (NCT06931769) to optimize neoadjuvant/adjuvant systemic therapy for stage III triple-…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer [Phase 2]
Phase 2 clinical trial update on the Triple-B study comparing carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumab as…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC [Phase 1]
Phase 1 clinical trial evaluating QL1706 in combination with short-cycle anthracyclines or taxanes for early-stage triple-negative breast ca…
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC [Phase 2]
A Phase 2 trial is evaluating Sac-TMT in combination with toripalimab as first-line therapy for PD-L1 positive advanced/metastatic triple-ne…
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis
This clinical trial update describes a flow cytometry-based neutrophil biomarker test intended to predict clinical benefit from immunotherap…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas [Phase 2]
Phase 2 study of LN-145 (LN-145-S1) in relapsed or refractory ovarian cancer, triple-negative breast cancer, anaplastic thyroid cancer, oste…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors. [Phase 2]
Phase II clinical trial evaluating multimodal ablation with systemic drug therapy for advanced solid tumors, currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) [Phase 3]
A Phase 3 trial in low-risk triple-negative early breast cancer is evaluating neoadjuvant sacituzumab govitecan alone versus sacituzumab gov…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer [Phase 2]
A Phase 2 clinical trial is evaluating datopotamab deruxtecan in combination with durvalumab versus datopotamab deruxtecan alone in PD-L1-ne…
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery [Phase 2]
A Phase 2 trial testing capecitabine plus pembrolizumab in triple-negative breast cancer after chemo-immunotherapy and surgery is currently …
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression [Phase 1, Phase 2]
Clinical trial update for BT5528-100 (Phase 1/2) in EphA2-expressing advanced solid tumors. The study includes urothelial carcinoma, ovarian…
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC [Phase 2]
A Phase 2 clinical trial from UNICANCER evaluating pembrolizumab with chemotherapy or no treatment guided by tumor-infiltrating lymphocytes …
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer [Phase 2]
Phase 2 study updating SKB264 with or without KL-A167 for recurrent/metastatic HER2-negative breast cancer, including triple-negative and HR…
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies [Phase 1, Phase 2]
Clinical trial update for BT8009-100 in nectin-4 expressing advanced malignancies (Phase 1/2) with status ACTIVE_NOT_RECRUITING.
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer [Phase 2]
Phase 2 trial OCTANE assesses adjuvant liposomal doxorubicin and carboplatin for early-stage triple-negative breast cancer; the study is cur…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Neratinib in Combination With Ruxolitinib in Patients With mTNBC [EARLY_Phase 1]
An early-phase trial is investigating the combination of neratinib and ruxolitinib for metastatic triple-negative breast cancer and is curre…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC) [Phase 1]
Phase Ib study evaluating a low-dose oral cyclophosphamide to potentiate axatilimab and retifanlimab in metastatic triple-negative breast ca…
-
CLINICAL_TRIALS research · 2025-11-05Clinical Trial Update: Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer [Phase 3]
This update describes a Phase 3 trial evaluating a shorter chemo-immunotherapy regimen that omits anthracyclines for early-stage triple-nega…
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) [Phase 2]
A Phase II neoadjuvant trial evaluating sacituzumab govitecan plus pembrolizumab in immunochemotherapy-resistant, early-stage triple-negativ…
-
CLINICAL_TRIALS research · 2025-10-30Clinical Trial Update: Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC [Phase 2]
This Phase 2 neoadjuvant trial evaluates darolutamide alone or with standard therapy in AR-positive stage II-IIIA breast cancer, including t…
-
CLINICAL_TRIALS research · 2025-10-29Clinical Trial Update: Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC [NA]
This clinical trial update notes that the LEAN trial from Yale University is actively recruiting to assess whether lifestyle, exercise, and …
-
CLINICAL_TRIALS research · 2025-10-24Clinical Trial Update: NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy [Phase 1]
A Phase 1 trial evaluating NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy for patients with advanced cancers; the st…